Lupin Names Industry Veteran Abdelaziz Toumi As CEO Of New API CDMO Subsidiary

Global pharmaceutical company Lupin Limited has named Abdelaziz Toumi as the CEO of its newly established subsidiary, Lupin Manufacturing Solutions (LMS). LMS focuses on the development, production, and sale of active pharmaceutical ingredients (APIs) and is beginning to expand its contract development and manufacturing operations (CDMO) business.

Toumi brings over 20 years of experience in the biotech, pharma, and CDMO industries across Europe, North America, and Asia. He has previously held leadership roles at Bayer, Merck, Catalent, Lonza, and KBI Biopharma, where he led initiatives in growth, innovation, and operational excellence. Based in Switzerland, Toumi will also spend significant time in India.

Toumi earned a Doctorate in Chemical Engineering and a Master’s in Business Administration from the University of Southern Queensland. Nilesh Gupta, Managing Director of Lupin, said, “We are delighted to welcome Abdel to our team. He brings a wealth of knowledge and experience in the API CDMO space and will be instrumental in establishing LMS as a trusted and preferred partner for our global customers.”